Peptide vaccines articles within Nature

Featured

• Article
  17 May 2023 | Open Access

  Microbial peptides activate tumour-infiltrating lymphocytes in glioblastoma

  Tumour-infiltrating lymphocytes from glioblastoma can recognize bacterial and gut microbial peptides.

  • Reza Naghavian
  • , Wolfgang Faigle
  •  & Roland Martin

• Article
  23 November 2021 | Open Access

  A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity

  A phase I open-label trial evaluating the immunogencity, reactogenicity and safety of a peptide-based SARS-CoV-2 vaccine candidate to induce SARS-CoV-2-specific T cell responses.

  • Jonas S. Heitmann
  • , Tatjana Bilich
  •  & Juliane S. Walz

• Letter | 19 December 2018

  Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial

  Neoantigen-targeting vaccines are a feasible therapy for tumours with a low mutation burden and immunologically ‘cold’ tumour microenvironment, as neoantigen-specific T cells from the peripheral blood migrate into intracranial glioblastoma, thereby altering the immune milieu of the glioblastoma.

  • Derin B. Keskin
  • , Annabelle J. Anandappa
  •  & David A. Reardon

• Letter | 05 July 2017

  An immunogenic personal neoantigen vaccine for patients with melanoma

  The results of a phase I trial assessing a personal neoantigen multi-peptide vaccine in patients with melanoma, showing feasibility, safety, and immunogenicity.

  • Patrick A. Ott
  • , Zhuting Hu
  •  & Catherine J. Wu